Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5198008
Max Phase: Preclinical
Molecular Formula: C40H52N6O6
Molecular Weight: 712.89
Associated Items:
ID: ALA5198008
Max Phase: Preclinical
Molecular Formula: C40H52N6O6
Molecular Weight: 712.89
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)CCN1CCC(Oc2ccccc2Cc2ccccc2)CC1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C40H52N6O6/c1-27(2)37(40(51)42-26-36(48)43-28(3)39(50)44-33(38(41)49)25-30-14-8-5-9-15-30)45-35(47)20-23-46-21-18-32(19-22-46)52-34-17-11-10-16-31(34)24-29-12-6-4-7-13-29/h4-17,27-28,32-33,37H,18-26H2,1-3H3,(H2,41,49)(H,42,51)(H,43,48)(H,44,50)(H,45,47)/t28-,33+,37-/m0/s1
Standard InChI Key: YFTDYJSGMITWBN-XBZKGDHESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 712.89 | Molecular Weight (Monoisotopic): 712.3948 | AlogP: 2.49 | #Rotatable Bonds: 18 |
Polar Surface Area: 171.96 | Molecular Species: BASE | HBA: 7 | HBD: 5 |
#RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.87 | CX Basic pKa: 8.73 | CX LogP: 2.67 | CX LogD: 1.33 |
Aromatic Rings: 3 | Heavy Atoms: 52 | QED Weighted: 0.13 | Np Likeness Score: -0.62 |
1. Kok ZY, Stoddart LA, Mistry SJ, Mocking TAM, Vischer HF, Leurs R, Hill SJ, Mistry SN, Kellam B.. (2022) Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor., 65 (12.0): [PMID:35734860] [10.1021/acs.jmedchem.2c00125] |
Source(1):